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Objective: We performed a comprehensive assessment of TH17
cells, regulatory T cells, mucosal-associated invariant T (MAIT)
cells, other T-cell subsets, and granulocyte mediators in
asthmatic patients.
Methods: Sixty patients with mild-to-severe asthma and 24
control subjects underwent detailed clinical assessment and
provided induced sputum, endobronchial biopsy,
bronchoalveolar lavage, and blood samples. Adaptive and
invariant T-cell subsets, cytokines, mast cells, and basophil
mediators were analyzed.
Results: Significant heterogeneity of T-cell phenotypes was
observed, with levels of IL-13–secreting T cells and type 2
cytokines increased at some, but not all, asthma severities. TH17
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http://dx.doi.org/10.1016/j.jaci.2015.01.014severe neutrophilic forms. MAIT cell frequencies were
strikingly reduced in both blood and lung tissue in relation to
corticosteroid therapy and vitamin D levels, especially in
patients with severe asthma in whom bronchoalveolar lavage
regulatory T-cell numbers were also reduced. Bayesian network
analysis identified complex relationships between pathobiologic
and clinical parameters. Topological data analysis identified 6
novel clusters that are associated with diverse underlying
disease mechanisms, with increased mast cell mediator levels in
patients with severe asthma both in its atopic (type 2 cytokine–
high) and nonatopic forms.
Conclusion: The evidence for a role for TH17 cells in patients
with severe asthma is limited. Severe asthma is associated with a
striking deficiency of MAIT cells and high mast cell mediator
levels. This study provides proof of concept for disease
mechanistic networks in asthmatic patients with clusters that
could inform the development of new therapies. (J Allergy Clin
Immunol 2015;nnn:nnn-nnn.)
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Asthma is characterized by airways inflammation and remodel-
ing. Based on initial studies in animal models1 and human T-cell
clones2 and bronchoscopic studies in patients with mild steroid-
naive asthma,3,4 it has been viewed as a disease driven by activated
TH2 cells producing the type 2 interleukins IL-4, IL-5, and IL-13.
These cytokines are believed to orchestrate the functions of mast
cells,5,6 eosinophils,7 and IgE-producing B cells/plasma cells.
This concept has been challenged with increasing recognition of
considerable heterogeneity of asthma mechanisms and definable
patient subpopulations associated with immunopathology that
cannot be explained by TH2 inflammation alone.
8-11 Discoveries
of novel T-cell subsets, notably anti-inflammatory regulatory T
(Treg) cells12,13 and proinflammatory IL-17–secreting (TH17)
14
and invariant natural killer15T cells,which are implicated in asthma
pathogenesis on the basis of studies in animal models and limited
evidence in human asthma, have added complexity to our under-
standing of immunoregulation. Recent studies have revived interest
inmast cells,6,16 a subject of intense research in the 1980s and early
1990s but not widely seen as candidate targets, possibly because of
limited evidence of their role in severe disease.6,17,18
Most studies of asthma pathobiology to date have focused on
individual or limited numbers of inflammatory cell types, making
it difficult to appreciate the cell-cell interactions within
complex networks that characterize inflammatory diseases, such
as asthma. Therefore we have undertaken a comprehensive
assessment of bronchial and circulating T cells, including1
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not yet studied in patients with asthma or other chronic lung dis-
eases, and relevant TH2/TH1/TH17 cytokines, as well as mediators
released in the lungs by mast cells and basophils. We have com-
bined these pathobiologic findings with standard clinical param-
eters used to define asthma severity20 and interrogated the rich
multidimensional clinicopathobiologic data set using the novel
techniques of the machine learning approach (ie, Bayesian
network analysis [BNA] and topological data analysis
[TDA]).21,22 This enabled an in-depth investigation of the roles
of individual cell types in relation to asthma severity, character-
ization of the complex interconnectivity between the diverse clin-
ical and pathobiologic parameters, and identification of
clinicopathobiologic clusters that could point to novel asthma
endotypes.METHODS
Participants
Eighty-four participants (18-70 years) were enrolled from the Wessex
Severe AsthmaCohort, NIHRSouthamptonRespiratory Biomedical Research
Unit, and outpatient clinics at University Hospital Southampton: 24 healthy
nonatopic participants, 15 patients with mild asthma receiving b2-agonists
alone, 23 patients with moderate asthma receiving inhaled corticosteroids
(ICSs), and 22 patients with severe asthma with persistent symptoms despite
high-dose ICSs (n5 16) and oral corticosteroids (n5 6, Table I and see Fig E1
in this article’s Online Repository at www.jacionline.org) classified on enroll-
ment according to previously used criteria (see Table E1 in this article’s Online
Repository at www.jacionline.org).15 One hundred seven participants were
consented to achieve an approximate minimum group size of 15, according
to the physician’s assessment of severity at enrollment, which was estimated
to provide 80% power at the .05 significance level to detect differences in the
primary outcomes of TH17 andMAIT cell frequencies in each tissue compart-
ment after loss of missing data.Study procedures
Participants were assessed based on history, examination results, skin prick
test responses to common aeroallergens, spirometric results, exhaled nitric
oxide (eNO) levels, serum IgE levels, and (except for patients with severe
asthma) methacholine responsiveness. Lung samples were obtained by means
of sputum induction,23 bronchoalveolar lavage (BAL), and endobronchial bi-
opsy.15,17 By using flow cytometry, the following T-cell subsets were charac-
terized by their surface markers and intracellular cytokines15 in the circulation
(blood) and lungs (sputum and BAL cell pellets; cells from collagenase-
dispersed endobronchial biopsy specimens were used to provide bronchial
mucosal cells): TH17-cells, TH1-cells, and IL-13–secreting-TH2 cells;
CD31CD41 (or CD82) forkhead box protein 3 (FOXP3)1 Treg cells;cytotoxic T (Tc) cells (TC1 and TC2); gd-17 T cells; and MAIT cells. Like
other authors,24 we could not detect with confidence IL-4– or IL-5–secreting
T cells using intracellular cytokine staining. Levels of type 1 (IFN-g, IL-2, and
12p70) and type 2 (IL-4, IL-5, and IL-13) cytokines, IL-10, IL-17A, mast cell
proteases, and basophil-derived basogranulin were measured in serum,
sputum, and BAL fluid by using standard methods (for details, see the
Methods section, Table E2 and Fig E2 in this article’s Online Repository at
www.jacionline.org).
The study was approved by the Southampton and South West Hampshire
Research Ethics Committee B. All participants provided informed consent.Statistical analysis
Data were first analyzed by using standard statistical methods, classifying
subjects as healthy or having mild, moderate, or severe asthma as defined
above and in the Methods section in this article’s Online Repository.15 BNA
was then applied to all the pathobiologic and clinical features to seek associ-
ation in relation to asthma severity. Finally, TDAwas applied to the same data
to create a network of distinct clinicopathobiologic clusters.Data elaboration and standard statistics
Data distribution was tested by using the Shapiro-Wilk test, and data were
logarithmically transformed if they were not normally distributed. For all
analyses, 2-tailed P values of less than .05 were considered significant. Data
were compared between the healthy and control groups (Mann-WhitneyU or
Student t tests) and between each asthma severity group and the control sub-
jects (Kruskal-Wallis test or ANOVA), depending on the distribution of the
data. For the latter, an overall 5% significance level was adjusted for multiple
comparisons by using the Bonferroni method. Groups ranked according to
disease severity were tested for linear trend by using polynomial contrasts
(or the Jonckheere-Terpstra test, if not normally distributed). Data are ex-
pressed as medians with interquartile ranges (IQRs) unless stated otherwise.
Correlations were tested by using the Spearman r coefficient. Kolmogorov-
Smirnov tests identified significant differences between distributions within
a single cluster. Data were analyzed with Prism 6.0 (GraphPad Software, San
Diego, Calif) and SPSS 21.0 (IBM, Armonk, NY) software.Network analyses
For network analyses (BNA and TDA), data were used from 62 participants
with the most complete data. Missing data were imputed by using average
values specific to each tissue and disease severity subgroup.A composite value
was generated for each parameter by using a weighted average across each
compartment: sputum and BAL fluid for concentrations of soluble mediators
and blood, sputum, BALfluid, and biopsy specimens for cell counts, providing
airway and tissue composite readouts, respectively, with a matrix of 62
participants and 26 pathobiologic and 26 clinical parameters (see theMethods
section and Tables E2 and E3 in this article’s Online Repository at www.
jacionline.org for definitions of terms). Interconnectivity between clinical
and pathobiologic parameters was first explored with BNA (Genie 2.0; Deci-
sion Systems Laboratory, Pittsburgh, Pa). Data were discretized to describe
nonlinear correlations into 2 bins for binary variables or 5 to 9 bins for contin-
uous variables.TDA
To use the full range of available clinical and pathobiologic data
simultaneously to identify multidimensional features within the data set,
which might not be apparent with traditional methods, we used the novel
technique of TDA, which is particularly suited to complex biological data
sets. This approach represents a high dimensional data set as a structured
3-dimensional network in which each ‘‘node’’ comprises subjects similar to
each other in multiple dimensions. Lines or ‘‘edges’’ are drawn between
nodes that contain shared data points. Statistical tests can then be performed
on groups or features that emerge from the inherent structure of the data set.
This method combines features of standard clustering methodologies and
TABLE I. Clinical characteristics of participants
Parameters
Healthy control
subjects
Patients with
mild asthma
Patients with
moderate asthma
Patients with
severe asthma
No. 24 15 23 22
Demographics
Sex (M/F), no. (%) 14 (58)/10 (42) 8 (53)/7 (47) 10 (43)/13 (57) 8 (36)/14 (64)
Age (y), median (range) 28 (20-65) 26 (21-64) 36 (21-56) 53 (23-67)
Pulmonary function
FEV1 (% predicted) 108 (105-113) 88 (86-103) 99 (86-107) 65 (49-82)
FEV1 reversibility (%) 3.3 (1.8-7.4) 13 (11-19) 10 (2.2-17) 13 (2.6-25)
PEFR (% predicted) 108 (97-116) 98 (89-107) 95 (85-100) 70 (53-82)
PEFR variability (%) 0 (0-11) 17 (10-25) 22 (17-32) 17 (12-24)
PD20 (mg methacholine) Negative 0.19 (0.050-0.79) 0.25 (0.063-0.73) Not done
eNO (ppb [at 50 L/s]) 16 (11-21) 53 (27-107) 26 (15-51) 20 (13-38)
Clinical
Atopy (positive skin test result, Y/N), no. (%) 0 (0)/24 (100) 15 (100)/0 (0) 20 (87)/3 (13) 15 (68)/7 (32)
No. of positive skin test results to allergens 0 (NA) 6 (4-7) 3 (2-5) 3.5 (0-5.3)
Peripheral eosinophil count (109/L) 0.1 (0.1-0.2) 0.2 (0.1-0.6) 0.2 (0.15-0.3) 0.2 (0.1-0.3)
Total IgE (IU/mL) 26 (10-61) 172 (21-451) 105 (35-188) 84 (31-669)
Body mass index (kg/m2) 24.4 (22.5-28.1) 23.6 (22.7-26.5) 25.3 (23.3-30.9) 31.0 (27.1-40.9)
Smoking status
Never smoker, no. (%) 21 (88) 14 (93) 19 (83) 17 (77)
Former smoker, no. (% [mean pack-years]) 3 (13 [4.2]) 1 (7 [6.7]) 4 (17 [5.8]) 4 (18 [26])
Current smoker, no. (% [mean pack-years]) 0 (0) 0 (0) 0 (0) 1 (5 [49])
Duration of asthma (y) NA 18 (15-26) 22 (9-27) 36 (21-49)
ACQ score NA 0.60 (0.43-1.3) 1.0 (0.60-1.4) 2.8 (2.2-3.5)
GINA level of control, no. (%)
Controlled NA 8 (53) 5 (22) 0 (0)
Partly controlled NA 6 (40) 15 (65) 2 (9.5)
Uncontrolled NA 1 (6.7) 3 (13) 19 (90)
Treatment
Inhaled steroids No No Yes Yes
Dose (equivalent mg BDP) NA NA 400 (200-400) 1600 (1280-2000)
Maintenance oral corticosteroids (Y/N), no. (%) No No No 6 (27)/16 (73)
Mean dose if taken (mg prednisolone/d) 11
Short-acting b-agonist (Y/N), no. (%) No Yes Yes Yes
Long-acting b-agonist (Y/N), no. (%) No No 10 (43)/13 (57) 22 (100)/0 (0)
Leukotriene receptor antagonist (Y/N), no. (%) No No 1 (4)/22 (96) 15 (68)/7 (32)
Step on GINA treatment algorithm NA 1 2-3 4-5
Inflammatory subtype, no. (%)
Total with valid data 16 13 18 21
Neutrophilic 4 (25) 2 (15) 2 (11) 10 (48)
Eosinophilic 1 (6.3) 3 (23) 3 (17) 6 (29)
Mixed granulocytic 0 (0) 0 (0) 0 (0) 1 (4.8)
Paucigranulocytic 11 (69) 8 (62) 13 (72) 4 (19)
Sputum cell differential (%)
Macrophages 52 (31-66) 49 (35-64) 47 (30-62) 30 (19-43)
Neutrophils 31 (11-65) 34 (22-54) 33 (16-56) 61 (32-76)
Epithelial 3.6 (2.0-24) 4.3 (1.7-10) 4.1 (1.1-21) 2.9 (0-7.8)
Eosinophils 0.38 (0-0.94) 1.5 (0.75-1.8) 0.75 (0.25-1.5) 0.69 (0-6.1)
Lymphocytes 0.1 (0-0.75) 0.3 (0-0.75) 0 (0-0.68) 0.0 (0-0.25)
BAL cell differential (%)
Macrophages 84 (74-89) 70 (60-80) 81 (73-89) 72 (46-94)
Neutrophils 2.5 (1.0-5.9) 2.5 (1.6-4.8) 3.5 (1.8-6.4) 6.5 (1.4-29)
Epithelial cells 9.9 (3.9-18) 21 (13-35) 11 (5.6-19) 8.7 (3.3-11)
Eosinophils 0.25 (0.0-0.56) 2.0 (0.75-3.6) 1.0 (0-3.0) 0.1 (0-1.6)
Lymphocytes 1.4 (0.94-2.4) 1.5 (0.38-3.0) 1.3 (0.5-2.3) 1 (0-1.6)
Relevant comorbidities, no. (%)
Allergic rhinitis 0 (0) 12 (80) 11 (58) 10 (46)
Nasal polyps 0 (0) 0 (0) 1 (5.3) 5 (23)
Eczema 3 (13) 7 (47) 6 (32) 4 (19)
Bronchiectasis 0 (0) 0 (0) 1 (5.3) 1 (4.5)
Values are medians with IQRs, unless stated otherwise. The inflammatory subtype is based on sputum differentials using the following cut points: neutrophilic, >61%; eosinophilic,
>3%. Percentages given are derived from subjects with valid data.
BDP, Beclomethasone dipropionate; NA, not available; PEFR, peak expiratory flow rate.
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FIG 1. Frequencies of CD31CD41 T cells expressing IL-13 (TH2 cells; A), IL-17 (TH17 cells; B), and FOXP3
(Treg cells; C) in PBMCs, sputum, BAL fluid, and bronchial biopsy specimens as a percentage of live
CD31CD41 T cells or, for endobronchial biopsy specimens, a percentage of CD31CD82 T cells. Horizontal
lines show medians. Left columns, Healthy control subjects versus asthmatic patients with Mann-
Whitney U P values. Right 3 columns, Stratified by disease severity with Kruskal-Wallis P values (P < .05).
*P < .05 and **P < .01, post hoc Dunn test compared with healthy subjects.
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4 HINKS ET ALalso provides a geometric representation of the data.21,22 In contrast to most
other techniques that depend on prior hypotheses and that focus on pairwise
relationships within the data,25 this geometric visualization allows recogni-
tion of multidimensional features (patterns) within the data in a less super-
vised, data-driven manner to identify meaningful subgroups that become
apparent (self-define themselves) on visualization (please see the TDA plots).
In addition, TDA does not require an a priori definition of the number of clus-
ters anticipated.
TDA was performed, as previously described,21 with IRIS 2.0 software
(Ayasdi, Palo Alto, Calif), constructing networks with parameters from
Table E3. Three inputs were used: a distance metric, 1 or more filter functions,
and 2 resolution parameters (‘‘resolution’’ and ‘‘percent overlap’’ or ‘‘gain’’).
A network of nodes with edges between them was created by using a force-
directed algorithm. The nodes represent bins or ‘‘microclusters’’ of data
points, and 2 nodes are connected if their corresponding collections of data
points have a point in common.21 Variance-normalized Euclidean distance
was used as a distance metric, with 2 filter functions: principal and secondary
metric singular value decomposition (for further explanation, see the Methods
section in this article’s Online Repository). Resolution and gain settings were
selected where the network structure permits identification of subgroups.
Kolmogorov-Smirnov tests identified parameters that differentiate each sub-
group from the rest of the structure and create clusters. Comparisons between
multiple clusters used 1-way ANOVA, with post hoc tests with the Bonferroni
correction.For additional methods used, see the Methods section in this article’s On-
line Repository.RESULTS
Data were first analyzed by using standard statistical methods
without imputation or composite averages, classifying subjects as
healthy or as having mild, moderate, or severe asthma (see Table
E1 and the Results section in this article’s Online Repository at
www.jacionline.org). Previous observations that mild steroid-
naive asthma is characterized by a bias toward type 2 inflamma-
tion were confirmed, with increased numbers of IL-13–secreting
CD41 (TH2) cells in sputum, BAL fluid, and endobronchial bi-
opsy specimens from patients with mild asthma (Fig 1, A) and ra-
tios of IL-13– to IFN-g–secreting CD41 (TH1) cells (see Fig E3 in
this article’s Online Repository at www.jacionline.org). However,
this bias was not seen in patients with severe asthma, in whom fre-
quencies of IL-13–secreting TH2 cells were not significantly
different from those in healthy subjects, although we did not mea-
sure frequencies of IL-4– or IL-5–secreting T cells. Similarly, in
patients with mild asthma, there were significant increases in
median concentrations of the type 2 cytokines IL-5 (median,
J ALLERGY CLIN IMMUNOL
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HINKS ET AL 50.13 pg/mL; IQR, 0.05-0.19 pg/mL) compared with those in
healthy subjects (0.003 pg/mL; IQR, 0.001-0.006 pg/mL; P <
.001) and IL-13 (0.009 pg/mL; IQR, 0.0009-0.026 pg/mL)
compared with those in healthy subjects (0 pg/mL [IQR, 0-
0.0008 pg/mL]; P < .05) in BAL fluid (see Fig E4 in this article’s
Online Repository at www.jacionline.org). In sputum neither IL-5
nor IL-13 levels were increased in patients with mild or moderate
asthma. In patients with severe asthma, IL-5 levels were also
significantly increased in both BAL fluid (0.015 pg/mL; IQR,
0.007-0.19 pg/mL; P < .05) and sputum (6.18 pg/mL; IQR,
3.13-14.8 pg/mL) compared with levels seen in healthy subjects
(1.19 pg/mL; IQR, 1.0-2.2 pg/mL; P5 .005; see Fig E4, B), sug-
gesting that its secretion might be relatively steroid insensitive
and might be derived from cellular sources other than airway
TH2 cells.
Analysis showed no significant differences in TH17 cell or gd-
17 T-cell frequencies between asthmatic patients and healthy sub-
jects (Fig 1,B, and see Fig E5 in this article’s Online Repository at
www.jacionline.org). Furthermore, we found no evidence of dys-
regulation of the TH17 response during cold-induced exacerba-
tions of asthma (see the Results section and Figs E6 and E7 in
this article’s Online Repository at www.jacionline.org). Likewise,
IL-17 levels were not increased in BAL fluid, sputum, or serum
from asthmatic patients (see Fig E4, B, and data not shown; P >
.05 in all compartments). However, when asthma was stratified
according to severity, IL-17 levels in BAL fluid were increased
in patients with mild asthma (P 5 .04; see Fig E4, A). Increased
IL-17 levels were associated with the presence of allergic rhinitis
(0.017 pg/mL [IQR, 0.0065-0.043 pg/mL] if present and 0.005
pg/mL [IQR, 0.0033-0.010 pg/mL] if absent, P 5 .02), with
airway eosinophilia (rs5 0.34,P5.04) and high serum IgE levels
(rs 5 0.42, P 5 .007; see Fig E4, C).
TH17 cells share functionally and developmentally antagonistic
relationships with the immunoregulatory Treg cells that regulate
airway hyperresponsiveness in murine asthma models.26
We observed a slight but significant deficiency of BAL
CD41FOXP31 Treg cells in asthmatic patients (median fre-
quency, 5.3%; IQR, 4.3% to 8.2%) comparedwith those in healthy
subjects (8.1%; IQR, 5.6% to 10%; P5 .03; Fig 1, C), which was
restricted to patients with severe asthma (Fig 1, C) and was not
evident in blood, sputum, or bronchial biopsy specimens.
There was a striking deficiency of T-cell receptor
Va7.21CD1611MAIT cells in blood, sputum, and biopsy spec-
imens from asthmatic patients, which was related to disease
severity and treatment with ICSs (Fig 2 and see Fig E8 in this ar-
ticle’s Online Repository at www.jacionline.org). There was evi-
dence of seasonal variation in MAIT cell frequencies and
association with serum vitamin D3 concentrations and use of
oral corticosteroids (see the Results section and Fig E9 in this ar-
ticle’s Online Repository).
Application of BNA to pathobiologic and clinical features in
relation to asthma severity showed complex nonlinear associa-
tions (Fig 3). Five nodes (eNO, IL-17, IFN-g, neutrophils, and
vitamin D) without strong interactions with other parameters
were not connected and therefore remained outside the network.
The asthma severity node was strongly connected with mast cell
mediators, tryptase, chymase, and carboxypeptidase A3 and with
IL-13– and IFN-g–secreting CD81 cytotoxic T cells (TC2 and
TC1 cells, respectively). There was a strong negative association
between MAIT cell frequencies and ICS use that, in turn, was
positively associated with asthma severity.To look further for novel associations between clinical and
pathobiologic features, we applied TDA to all acquired clinical
and pathobiologic data (Figs 4 and 5 and see Table E4 in this ar-
ticle’s Online Repository at www.jacionline.org). Data were
treated as composite averages for T-cell subsets (across blood,
sputum, BAL fluid, and biopsy specimens), cytokines and eosin-
ophils (across blood, sputum, and BAL fluid), neutrophils, macro-
phages, lymphocytes, mast cell mediators, and basogranulin
(across sputum and BALfluid). One healthy and 6 asthma clusters
were identified.
The TDA-derived cluster 1, comprising predominantly patients
with mild atopic asthma, had (compared with other asthmatic
patients) better lung function, lower Asthma Control Question-
naire (ACQ)27 scores (mean, 0.88), and lower severity, as assessed
by a physician on enrollment or based on Global Initiative for
Asthma (GINA) criteria,20 and patients were mostly not receiving
ICSs. They had increased IL-13–secreting TH2 cell numbers and
lower IL-13 and tryptase levels andwere predominantly paucigra-
nulocytic (sputum neutrophils, <_61%; eosinophils, <_3%; Fig 4, B,
and see Table E4).
Cluster 2 consisted of patients with well-controlled asthma
(mean ACQ score, 0.5), with little evidence of inflammation (the
only abnormality being eosinophilia) and lower frequencies of
Treg cells and IFN-g–secreting CD81 T cells (Fig 4).
Cluster 3 consisted of patients with moderately severe (defined
by enrollment criteria) and partially controlled asthma (based on
GINA criteria20) despite ICSs; they had the highest bronchodi-
lator reversibility and eNO levels. Their pathobiologic profile
consisted of type 2 inflammation, with the highest levels of IL-
5 and IL-13 and high frequencies of IL-132secreting TH2 cells
in bronchial biopsy specimens (Fig 5, A, and see Figs E10 to
E12 in this article’s Online Repository at www.jacionline.org)
but also other T-cell subsets, TH1 cells, TH17 cells, and Treg cells.
Cluster 4 was a small group with later-onset (mean, 28 years)
moderately severe disease based on a physician’s assessment,
nasal polyposis, salicylate sensitivity, and low IL-17 levels.
Cluster 5 asthmatic patients were older (mean age, 50 years),
with high BMI (mean, 32.6 kg/m2), poor lung function, high
symptom scores (mean ACQ score, 2.1), and high treatment re-
quirements (predominantly GINA step 4-5 and a mean of 1500
mg/d beclomethasone dipropionate equivalent). Their pathobio-
logic profile was high type 2 cytokine levels (IL-5 and IL-13),
IL-13–secreting CD81 T (TC2) cells (see Fig E13, D, in this arti-
cle’s Online Repository at www.jacionline.org), and high tryp-
tase, chymase, and carboxypeptidase A3 levels (Figs 4 and 5,
C, and see Figs E10 to E12 in this article’s Online Repository).
However, when compared with cluster 3 (also type 2 cytokine
high), cluster 5 had fewer Treg cells and higher ICS use (mean dif-
ference, 1250 mg/d).
Cluster 6 was predominantly female, obese (mean BMI,
35 kg/m2), and nonatopic, with salicylate sensitivity and later
onset (mean age, 25 years). They were the most severe cluster
based on GINA classification, physician’s assessment, symptom
scores (mean ACQ score, 3.2), and lung function (mean prebron-
chodilator FEV1, 62%), despite high-dose ICSs (see Fig E12,B, in
this article’s Online Repository at www.jacionline.org) and,
frequently (50% of the group), maintenance oral corticosteroids
(mean, 14 mg/d prednisolone). Their key pathobiologic features
were high carboxypeptidase A3 levels and profound MAIT cell
deficiency (Figs 4, E, and 5, D, and see Fig E9, D). They also
had low TC1, TH17, and IL-132secreting TH2 cell numbers
A MAIT cells
M
A
IT
 c
el
l f
re
qu
en
ci
es
(%
 C
D
3+
 c
el
ls
)
0
2
4
6
8
10
M
A
IT
 c
el
l f
re
qu
en
ci
es
(%
 C
D
3+
 c
el
ls
)
PBMC Sputum BAL Biopsy
Healthy
Asthma
P=0 02P=0 002P=0.005
0 .0 1
0 .1
1
1 0 * ***
0.1
1
10 * **
0 .1
1
1 0
0 .1
1
1 0
Test for linear trend P <0 0001 Test for linear trend P=0 006
Healthy Mild Moderate Severe Healthy Mild Moderate Severe
B PBMC C Sputum
Healthy Mild Moderate Severe Healthy Mild Moderate Severe
D Bronchoalveolar lavage E Bronchial biopsies
FIG 2. MAIT cells (Va7.21CD1611) as proportions of CD31 T cells in blood, sputum, BAL fluid, and endobron-
chial biopsy specimens in healthy subjects and asthmatic patients (A) and stratified by disease severity (B).
Horizontal lines showmedians. Unpaired t testswere used for log-transformed data.MAIT cell deficiency cor-
relates with severity by linear trends across groups using residuals on log-transformed data (where P < .05).
*P < .05, **P < .01, and ***P < .001, post hoc Dunnett test compared with healthy subjects.
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6 HINKS ET AL(see Fig E9, A) but increased tryptase (Figs 4, E, and 5, C) and
chymase levels. This cluster contained a higher proportion of par-
ticipants who could be classified as cluster 5, as described by the
Severe Asthma Research Program9 (see Fig E13, B) and the
obese, noneosinophilic cluster reported by Haldar et al.10
The majority of participants with sputum neutrophilia, which
was defined as neutrophil numbers of greater than 61%,28 were in
clusters 5 and 6, whereas eosinophilic asthma was distributed
across clusters 1, 2, 3, and 5 but not clusters 4 or 6 (Fig 4, B).DISCUSSION
Asthma is a common diseasewith a clinical severity that ranges
frommild forms controlled withb2-agonists alone or low doses of
ICSs to very severe forms requiring high doses of ICSs and oral
corticosteroids and, increasingly, biologics, such as the anti-IgEmAb omalizumab.29 In this study comprehensive analysis of T
cells, granulocytes, cytokines, and mast cell mediators across
the airway lumen, mucosa, and blood compartments pointed to
their relative roles within the asthma syndrome that have not
been recognized before: reducedMAIT cell frequencies as a strik-
ing feature that is related to asthma severity, reduced Treg cell fre-
quencies in severe disease, and increased mast cell mediator
levels in patients with severe disease, which is consistent with
corticosteroid-insensitive mast cell activation. This study shows
that the asthma spectrum can be broken down into several multi-
dimensional clusters defined by combined clinical parameters and
underlying mechanisms (pathobiology), which provides proof of
concept for endotyping asthma for better understanding of its
mechanisms and more focused drug development.
Original descriptions of asthma pathobiology3 suggested a
key role for TH2 mechanisms. Consistent with this concept,
FIG 3. Bayesian belief network showing the strongest interactions between pathobiologic parameters
across a range of clinical severities of asthma or health. Nodes without strong interactions are excluded.
Line thickness represents strength of interaction (Euclidean distance). Line colors: green, positive associa-
tions; red, negative associations; black, nonlinear associations. Asthma severity is based on overall physi-
cian’s assessment at enrollment (see Table E1). BMI, Body mass index; TC1, CD8
1IFN-g1 T cells; TC2,
CD81IL-131 T cells.
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HINKS ET AL 7when all the asthmatic patients in this study were compared as a
group with healthy participants, the most significant asthma
discriminators were airway eosinophilia and higher levels of
mast cell mediators (carboxypeptidase A3, chymase, and tryp-
tase), IL-5, IL-13, eNO, and serum IgE but lower IFN-g levels,
a pathobiologic profile classically associated with TH2 inflam-
mation (Fig 1, A, and see Fig E11). The application of BNA
showed high connectivity between the asthma severity node
and nodes for mast cell mediators and IL-13– and IFN-
g–secreting CD81 cytotoxic T cells (TC2 and TC1 cells, respec-
tively) and a strong negative association between MAIT cell
frequencies and asthma severity and ICS consumption.
Applying the recently developed TDA method21,22 to the
same data set showed complex multidimensional clusters (ie,
possible endotypes defined by a combination of clinicopatho-
biologic features).8,11 The advantage of TDA over standard
clustering methodologies is that it provides geometric represen-
tations of complex and multidimensional data sets that reveal
and stratify distinct subgroups.22 It combines features of stan-
dard statistical methods, such as singular value decompositions
and similarity metrics, to construct a network that clusters most
similar data points into nodes. A node in a TDA network rep-
resents a group of most similar data points (in this case >_2 sub-
jects who are similar in multiple dimensions). Each node can be
joined to the next node if they share common data points (ie,
subjects). This allows a natural continuous network when the
phenomenon is not disjointed.21 TDA can deal with both linear
and nonlinear associations and identifies significant subgroupsin a data-driven manner, allowing for finer stratification.21
Furthermore, TDA is sensitive to both large- and small-scale
patterns that other techniques, such as clustering and multidi-
mensional scaling, often do not detect because they sometimes
obscure geometric features captured by using topological
methods. Hierarchical clustering cannot easily identify these
subgroups because it tends to separate points that might in
fact be close in the data.21
The finding of clinicopathobiologic clusters in the data set in
this study should improve our understanding of asthma and
inform drug development. Overexpression of the TH2 cytokine
network in cluster 1 is similar to the original reports in
corticosteroid-naive asthmatic patients, highlighting the role of
type 2 mechanisms in asthmatic patients.3 Clusters 3 and 5 share
many clinical features, including atopy, allergic rhinitis, and
emotion-related symptoms (see this article’s Online Repository).
Both are characterized by type 2 inflammation, with the highest
levels of IL-5, IL-13, and IL-10, suggesting that these clusters
reflect asthma endotypes that might be particularly suitable for bi-
ologics, such as mepolizumab30 and lebrikizumab,31 that
currently use indirect biomarkers (ie, eosinophil counts and serum
periostin levels) to select patients to maximize clinical efficacy.
However, important differences between these 2 clusters were
identified: higher Treg cell frequencies in cluster 3 might explain
their lower corticosteroid requirements, whereas lower IL-13–
secreting TH2 cell frequencies and higher tryptase levels in cluster
5 suggest distinct, steroid-insensitive mechanisms.32 It should be
noted that we stained only for IL-13, and therefore we cannot
FIG 4. A,Multidimensional clinicopathobiologic clusters in asthmatic patients and healthy subjects. Topo-
logical network analysis of clinical and pathobiologic features generates 1 healthy (blue) and 6 distinct clin-
icopathobiologic asthma clusters (1-6). The network is colored by disease severity (GINA classification),
with patients with the most severe disease in red and patients with the milder forms in varying shades of
orange, yellow, and green. B, The same network as Fig 4, A, overlaid with distribution of neutrophilic
(sputum neutrophils >61%, green) or eosinophilic (sputum eosinophils >3%, red) asthma. C, Frequencies
of MAIT cells. D, The network is colored based on average concentrations of the type 2 cytokines IL-4, IL-
5, and IL-13 in serum, sputum, and BAL fluid. E, The network is colored based on concentrations of mast
cell tryptase in sputum and BAL fluid. In Fig 4, B-E, the colors represent concentrations or frequencies,
ranging from low (blue) to high (red) concentrations. The TDA used 62 subjects with most complete
data. The variance normalized Euclidean metric was used. The lenses used were principal and secondary
singular value decomposition (resolution, 32; gain, 4.0/3.53; equalized). Node size is proportional to the
number of subjects in the node.
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8 HINKS ET ALexclude an increase in TH2 cells secreting IL-4 or IL-5 in themore
severe asthma clusters. We observed some differences between
patterns of cytokine secretion in sputum and BAL fluid, which
might arise because BAL samples the distal airways and alveoli,
whereas sputum measurement reflects changes in more proximal
airways.33The strong association between asthma severity and mast cell
mediator levels in clusters 5 and 6 suggests that severe asthma is a
disease in which mast cell activation plays an important role. Our
data add to evidence implicating mast cells in patients with severe
asthma, providing additional confirmation that should stimulate
the development of drugs that target mast cells. Brightling et al6
FIG 5. Analysesgenerated fromtheclinicopathobiologicTDAnetwork inFig4showconcentrationsof IL-5aver-
agedacross serum, sputum,andBALfluid (A); eNOconcentrations (B);mast cell tryptase levels inBALfluidand
sputum (C); andMAIT cells in blood, sputum, BAL fluid, and bronchial biopsy specimens (D). Box and whisker
plots showmedians, IQRs, and ranges. Statistical tests indicate 1-way ANOVA, with post hoc t tests compared
with healthy subjects by using the Bonferroni correction. *P < .05, **P < .01, and ***P < .001.
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infiltrating the airway smoothmuscle in patients withmild and se-
vere34 asthma in numbers that correlate with airway hyperrespon-
siveness.6,18 In the Severe Asthma Research Program Balzar
et al16 reported that severe asthmawas associated with an increase
in numbers of bronchial mast cells staining positive for both tryp-
tase and chymase and with BAL concentrations of PGD2, a lipid
mediator associated with mast cells and shown to increase after
allergen challenge.5
The current study adds to the evidence5,16,35 that mast cell acti-
vation is insensitive to corticosteroids and suggests that patients
with severe asthma, in whom mast cell mediator levels are
increased, can be stratified further by clinical features, such as
atopic status and also by evidence of type 2 cytokine–mediated
mechanisms in cluster 5 but not cluster 6. We speculate that the
anti-IgE antibody omalizumab might exhibit some of its benefi-
cial effects in patients with severe atopic asthma through inhibi-
tion of IgE-mediated mast cell activation. This finding might
yield a prognostic biomarker for this biologic, which is currently
missing, and could extend the indication for omalizumab to non-
atopic asthma, in which a preliminary trial has suggested clinical
efficacy.36
Several asthma studies have reported increased IL-17
levels,37,38 but this study found only limited evidence for TH17
cells and none for gd-17 cells during either a period of clinical sta-
bility or an exacerbation. This is consistent with the findings of a
recent trial in which the anti–IL-17 receptor A mAb brodalumab
had no effect on symptoms or lung function in patients with
moderate-to-severe asthma.39 However, we observed associations
between IL-17 concentrations and levels of traditional type 2biomarkers (airways eosinophils and serum IgE) that have not
been reported before because IL-17 has mainly been implicated
in neutrophilic inflammation in asthmatic patients.40
Our study also identified, for the first time, reduced numbers of
CD31CD41FOXP31Treg cells in patients with severe asthma. In
human subjects some upregulation of the nuclear transcription
factor FOXP3 has been observed in nonsuppressive T cells on
T-cell receptor stimulation.41 Although we were not able to
further validate the identity of these FOXP31 TH cells as Treg
cells with additional surface markers, we observed low rates of
spontaneous T-cell activation, suggesting that activated T cells
will comprise only a small proportion of the CD31CD41FOXP1
T cells enumerated.
An important finding in this study is the striking deficiency of
MAIT cells in both the circulation and lungs, which correlated
strongly with clinical severity. To our knowledge, MAIT cells
have not yet been studied in any airways disease. This study
suggests that they are more abundant than invariant natural killer
T cells,15 comprising up to 10% of blood and airway T cells. Their
marked evolutionary conservation implies an important role in
immunity.42,43 MAIT cells are the most abundant T-cell subset
able to detect and kill bacteria-infected cells. Recent animal
models of bacterial airways infection indicate their critical role
in lung host defense.42,44 We found MAIT cell frequencies to
be associated with serum vitamin D3 concentrations and in pilot
data could be suppressed by 1 week of treatment with predniso-
lone (see Fig E14 in this article’s Online Repository at www.
jacionline.org). The lack of a significant deficiency ofMAIT cells
in BAL fluid might result from low peripheral deposition of ICSs
in the more distal airways and alveolar compartments sampled by
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10 HINKS ET ALmeans of lavage.33 Their deficiency in patients with severe
asthma, whether primary or resulting from chronic corticosteroid
use, can contribute to increased susceptibility to bacterial infec-
tion recognized in patients with severe asthma45,46 and to changes
in the airway microbiome47 and might thus effect asthma
pathology.44
In summary, this study sheds light on previously unreported
observations in asthma in relation to disease severity. The
observation of clusters composed of clinical and pathobiologic
parameters will need to be reproduced before these clusters can be
accepted as novel endotypes of asthma. However, this paves the
way for future asthma studies in large patient cohorts, such as the
Severe Asthma Research Program9 and Unbiased BIOmarkers in
PREDiction of respiratory disease outcomes (U-BIOPRED),48 in
which distinct asthma endotypes could be identified and subse-
quently validated, allowing translation to clinical trials and
routine clinical practice.
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possible.
Key messages
d We provide proof of concept for a powerful new analytic
approach to defining multidimensional clinical and path-
obiologic clusters: TDA. This underlines the role of mast
cells in 2 distinct subgroups of patients with severe
asthma characterized by the presence or absence of
type 2 responses.
d Evidence supporting a role for TH17 cells in patients with
severe asthma is limited.
d We describe a striking deficiency of mucosal-associated T
cells, as well as a mild reduction in Treg cell numbers, in
patients with severe asthma.REFERENCES
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